Lenalidomide Pharmascience (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding triggers the degradation of transcription factors Ikaros and Aiolos, leading to reduced proliferation, increased apoptosis, and inhibition of angiogenesis in malignant plasma cells and dysplastic clones.

The specific dose and schedule of Lenalidomide Pharmascience are determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Patients should follow the prescriber’s instructions precisely.

Lenalidomide is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. Women of child‑bearing potential must use effective contraception, and breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering a distinct mechanism of action compared with proteasome inhibitors or monoclonal antibodies. It is often combined with dexamethasone or used in combination regimens, providing synergistic anti‑myeloma activity and a different side‑effect profile.

Store Lenalidomide Pharmascience at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use.

Lenalidomide Pharmascience is taken orally, usually once daily, with or without food as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include severe neutropenia, thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, serious infections, secondary malignancies, and hepatotoxicity. Patients should be monitored regularly for blood counts, liver function and signs of clotting.

Lenalidomide should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled active infections. Caution is also advised for those with severe renal or hepatic impairment, and the drug is contraindicated with live vaccines.